Sector News

If Pfizer's consumer health unit goes up for grabs, Reckitt's interested, CEO says

December 7, 2015
Life sciences

As Pfizer moves forward with its agreed-upon $160 billion merger with Allergan, analysts expect it to eventually part ways with its consumer health business. And when it does, it’s got a potential buyer in Reckitt Benckiser.

An eventual divestment of the company’s consumer assets is “inevitable,” Exane BNP Paribas analysts wrote last month in a note seen by Bloomberg, and as Reckitt CEO Rakesh Kapoor told the news service on Friday, his company would be “very interested” in giving them a look.

For Reckitt, the addition of Pfizer’s OTC products–which generate about $3.5 billion annually–would boost its own consumer portfolio, which accounts for about 31% of overall revenue and currently provides the bulk of the company’s growth. A deal between the two would bring well-known brands like Advil, ChapStick and Centrum to a portfolio that already includes Nurofen painkillers and Durex condoms.

Pfizer, which helped pioneer Big Pharma’s slim-down trend with an $11.5 billion sale of its nutrition business to Nestlé and an IPO for its animal health unit, has for a while now been weighing a large-scale break up, and some industry watchers expect the Allergan transaction to speed that plan along.

And Reckitt hasn’t been shy when it comes to chasing Big Pharma castoffs. Last year, it raced Bayer nearly to the finish line for Merck’s ($MRK) consumer unit, though it eventually bowed out, allowing the German pharma to ink a $14.2 billion deal. The year prior, it struck a $482 million pact with Bristol-Myers Squibb to license some of the New Jersey drugmaker’s Latin American brands.

But if Pfizer’s unit does come up for grabs, Reckitt may be staring down some hefty competition. Bayer, for one, has said it’s gunning for the global No. 1 position in the OTC market–a space that recently changed hands when GlaxoSmithKline and Novartis teamed up to form an industry-leading joint venture. New Sanofi CEO Olivier Brandicourt also last month said he plans to build scale in consumer health through acquisitions.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.